Anhui Anke Biotechnology (Group) Co., Ltd.

Shenzhen Stock Exchange 300009.SZ

Anhui Anke Biotechnology (Group) Co., Ltd. EBIT for the year ending December 31, 2023: USD 129.84 M

Anhui Anke Biotechnology (Group) Co., Ltd. EBIT is USD 129.84 M for the year ending December 31, 2023, a 7.55% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Anhui Anke Biotechnology (Group) Co., Ltd. EBIT for the year ending December 31, 2022 was USD 120.72 M, a 143.71% change year over year.
  • Anhui Anke Biotechnology (Group) Co., Ltd. EBIT for the year ending December 31, 2021 was USD 49.53 M, a -21.69% change year over year.
  • Anhui Anke Biotechnology (Group) Co., Ltd. EBIT for the year ending December 31, 2020 was USD 63.26 M, a 140.82% change year over year.
  • Anhui Anke Biotechnology (Group) Co., Ltd. EBIT for the year ending December 31, 2019 was USD 26.27 M, a -41.17% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Loading...
Shenzhen Stock Exchange: 300009.SZ

Anhui Anke Biotechnology (Group) Co., Ltd.

CEO Mr. Jian Ping Yao
IPO Date Oct. 30, 2009
Location China
Headquarters AnkeBio Building
Employees 2,986
Sector Health Care
Industries
Description

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.

Similar companies

300122.SZ

Chongqing Zhifei Biological Products Co., Ltd.

USD 3.45

3.36%

300017.SZ

Wangsu Science & Technology Co.,Ltd.

USD 1.29

7.24%

300294.SZ

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

USD 3.99

1.96%

300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd

USD 0.51

3.91%

300142.SZ

Walvax Biotechnology Co., Ltd.

USD 1.59

4.31%

StockViz Staff

January 15, 2025

Any question? Send us an email